Comparing Journey Medical (NASDAQ:DERM) and Madrigal Pharmaceuticals (NASDAQ:MDGL)

Journey Medical (NASDAQ:DERM) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Journey Medical and Madrigal Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86 million	2.63	-$11.43 million	($0.37)	-16.11
Madrigal Pharmaceuticals	$958.40 million	12.45	-$288.28 million	($12.80)	-40.41

Journey Medical has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Journey Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Journey Medical and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%

Analyst Ratings

This is a breakdown of current ratings and target prices for Journey Medical and Madrigal Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1	1	2	0	2.25
Madrigal Pharmaceuticals	1	3	12	1	2.76

Journey Medical currently has a consensus price target of $13.00, suggesting a potential upside of 118.12%. Madrigal Pharmaceuticals has a consensus price target of $687.00, suggesting a potential upside of 32.82%. Given Journey Medical’s higher possible upside, equities analysts plainly believe Journey Medical is more favorable than Madrigal Pharmaceuticals.

Risk and Volatility

Journey Medical has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500.

Insider and Institutional Ownership

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 15.0% of Journey Medical shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Journey Medical beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.